General MedicationsORALGeneric

REBETOL

RIBAVIRIN

Standard Dose

200MG **Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetron Combination Therapy**

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview REBETOL is listed in Drugs@FDA under application 020903 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient RIBAVIRIN Form and strength CAPSULE;ORAL - 200MG **Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetron Combination Therapy** Sponsor MERCK SHARP DOHME Submission history Latest submission status date: 2022-03-16 00:00:00.

Structured Monograph

Clinical summary

Approval overview REBETOL is listed in Drugs@FDA under application 020903 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient RIBAVIRIN Form and strength CAPSULE;ORAL - 200MG **Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetron Combination Therapy** Sponsor MERCK SHARP DOHME Submission history Latest submission status date: 2022-03-16 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.